Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 April 2026, providing investors with the latest insights into its performance and outlook.

Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced improvement in technical indicators and valuation metrics despite ongoing fundamental challenges. The micro-cap pharmaceutical company’s recent price surge and valuation appeal have prompted this reassessment, though financial trends and quality scores remain subdued.

At Rs 32.28, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Biofil Chemicals & Pharmaceuticals Ltd locked at its upper circuit of 9.98% on 7 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO. This rating was last updated on 16 February 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 02 April 2026, providing investors with the latest perspective on the company’s position.

Biofil Chemicals & Pharmaceuticals Ltd’s stock price declined to a fresh 52-week low of ₹26.36 on 30 March 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting persistent challenges in its financial and market performance.

Despite a broadly positive market environment, Biofil Chemicals & Pharmaceuticals Ltd has succumbed to selling pressure, hitting a fresh 52-week low of Rs 27.99 on 27 Mar 2026. This decline comes amid a sharp underperformance relative to the Sensex, which itself is hovering near its own 52-week lows.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 March 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Biofil Chemicals & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Biofil Chemicals & Pharmaceuticals Ltd has touched a new 52-week low of Rs.28.01 today, marking a significant decline amid continued underperformance relative to its sector and benchmark indices. The stock has now recorded losses for three consecutive days, accumulating a negative return of 8.59% over this period.

Biofil Chemicals & Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its financial performance, valuation metrics, quality indicators, and technical outlook. The downgrade reflects a combination of flat recent financial trends, deteriorating profitability measures, and a valuation profile that, while attractive, is overshadowed by weak fundamentals and underwhelming market returns.

Biofil Chemicals & Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite ongoing sector headwinds and a challenging market environment. This recalibration in price-to-earnings (P/E) and price-to-book value (P/BV) ratios offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks.

Shares of Biofil Chemicals & Pharmaceuticals Ltd surged to hit the upper circuit limit on 9 Feb 2026, propelled by robust buying interest and a near 10% intraday gain. The stock’s performance outpaced its sector and benchmark indices, reflecting renewed investor confidence despite a recent downtrend.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 06 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Shares of Biofil Chemicals & Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, plunged sharply to hit the lower circuit limit on 5 Feb 2026, reflecting intense selling pressure and panic among investors. The stock closed at ₹37.54, down 10.0% on the day, marking its maximum permissible daily loss and underperforming both its sector and the broader market indices.